Anti-tumour activity of tachykinin NK1receptor antagonists on human glioma U373 MG xenograft by Palma, C et al.
Malignant astrocytomas or glioblastomas represent the most
common type of primary brain tumour in adults (Salcman and
Kaplan, 1986; Hochberg and Pruitt, 1987). High-grade malignant
gliomas are inevitably lethal neoplasms and the median survival of
patients treated with standard cytoreductive surgery and post-
operative radiotherapy is in the range of 1 year. Likewise chemo-
therapy is of limited effectiveness in the treatment of these
tumours and other therapeutic approaches must be explored.
Glioblastomas are sensitive to several hormones and growth
factors. The presence of receptors for epidermal growth factor,
platelet-derived growth factor, insulin-like growth factor-I/II as
well as for glucocorticoid, androstenedione and progesterone in
malignant gliomas, has been described (Shapiro et al, 1995).
Recently, neurotransmitters/neuropeptides have also been found to
regulate astrocytoma growth (Sharif, 1998).
Substance P (SP), an undecapeptide of the tachykinin family of
neuropeptides, is released both in the central and peripheral
nervous systems, playing a well established role in neuronal trans-
mission, vasodilatation and motor responses (Maggi et al, 1993).
Tachykinins exert their actions through activation of G-protein
coupled receptors, labelled NK1, NK2, NK3; SP is the preferential
endogenous ligand for the tachykinin NK1 receptor (Maggi et al,
1993; Otsuka and Toshioka, 1993). In various astrocytic/glial
brain tumour-derived cell lines, the presence of tachykinin NK1
receptor strictly correlates with the effect of SP and/or NKA in
increasing DNA synthesis and cellular proliferation (Luo et al,
1996; Sharif et al, 1996; Palma et al, 1999a). In addition, SP 
can control many other glial responses such as taurine release,
secretion of various cytokines (e.g. interleukin (IL)-6, IL-8, 
transforming growth factor-b, leukaemia inhibitory factor,
granulocyte–macrophage colony stimulating factor) which are
thought to be relevant for glioma progression (Gitter et al, 1994;
Palma et al, 1995; Palma and Manzini, 1998). In a large number of
these studies, the human astrocytoma grade III U373 MG cell line,
which expresses a high level of functional tachykinin NK1 receptor
(Lee et al, 1992; Palma et al, 1999b) but not tachykinin NK2 or
NK3 receptors (Heuillet et al, 1993), were used.
The role of SP in glioma activities may be ascribed to a patho-
logical use of normal signal transduction pathways occurring in
reactive astrocytes. In fact, SP activates phospholipase C and stim-
ulates the release of IL-6 and prostaglandin E2 from human fetal
astrocytes in culture (Palma et al, 1997), and there is evidence for
an up-regulation of this receptor by reactive proliferating astro-
cytes after transection of the optic nerve (Mantyh et al, 1989).
Moreover, SP-immunoreactive astrocytes have been observed in
multiple sclerosis plaques (Kostyk et al, 1989) and in the fore-
brains of human infants (Michel et al, 1986). Interestingly, the
involvement of tachykinin NK1 receptor and SP in glioma progres-
sion was not only supported by the functional in vitro studies on
human glioma cell lines but also by some clinical evidence. In
fact, astrocytoma and glioblastoma contain significant levels of
high affinity receptors for SP and their increase in expression
correlate with the most malignant phenotype (Henning et al,
1995). Moreover, the presence of the SP itself has been docu-
mented in human malignant glioma tissues (Allen et al, 1985).
In the last decades a wide range of antagonists highly specific
and selective for human tachykinin NK1 receptors have been
described with heterogeneous chemical structures and types 
of pharmacological antagonism (Quartara and Maggi, 1998).
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potent human tachykinin NK1 receptor antagonists. In radioligand
binding studies, conducted with [3H]SP on intact U373 MG cells,
these antagonists interacted with the receptor in an irreversible
manner and showed high affinity for the receptors with Ki values
of about 1nM(Cirillo et al, 1998a; Palma et al, 1999b). On the
contrary they had virtually no affinity (Ki values ³10000nM) for
rat or murine tachykinin NK1 receptors (Cirillo et al, 1998a,
1998b). Receptor blockade by both antagonists resulted in a
powerful and complete inhibition of functional U373 MG
responses induced by SP, such as accumulation of the second
messenger inositol monophosphate or interleukin-6 release (Palma
et al, 1999a, 1999b). Moreover, these antagonists were more
potent in inhibiting late rather than early phases of SP-induced
inositol monophosphate accumulation and their antagonisms were
enhanced by drug preincubation and barely affected by removal of
unbound drug from the external medium, suggesting that they
bound in a tight manner to the receptor (Palma et al, 1999b).
Interestingly, MEN 11467 was able to completely inhibit the SP-
induced proliferation, both in terms of DNA synthesis and increase
of cell number, in U373 MG cells without affecting both the basal
or IL-1b-stimulated cell growth (Palma et al, 1999a).
These findings prompted us to investigate the effects of
tachykinin NK1 receptor antagonists on the growth of human brain
tumours in in vivo mouse glioma xenograft model.
MATERIALS AND METHODS
Drugs
The tachykinin NK1 receptor antagonists, MEN 11467 ((1R,2S)-
2N[1(H)indol-3-yl-carbonyl]-1-N-{Na(p-tolylacetyl)-Na(methyl)-D-
3-(2-naphthyl)alanyl}diaminocyclohexane; MW = 600.8) (Cirillo et
al, 1998a; Palma et al, 1999b) and MEN 11149 (2-(2-naphthyl)-1-N-
{(1R,2S)-2-N-[1(H)indol-3-yl-carbonyl]aminocyclohexane
carbonyl}-1-[N¢-methyl-N¢-(4-methylphenylacetyl)]diaminoethane;
MW = 600) (Cirillo et al, 1998b), were synthesized at the Chemistry
Department of Menarini Ricerche, Pomezia, Italy (Figure 1). For the
purposes of this study, these antagonists were solubilized in dimethyl
sulphoxide (DMSO) and diluted in saline containing 6% Tween-80.
SP was purchased from Calbiochem-Novabiochem AG (Laufe-
lingen, Switzerland) solubilized in water and diluted in saline for
administration to mice. Doxorubicin was purchased as a pharmaceu-
tical formulation from Pharmacia Upjohn (Nerviano, Milan, Italy)
and freshly prepared before use.
Animals
Female athymic nu/nunude mice, 5–7 weeks old were purchased
from Harlan Nossan S.r.l. (Corezzana, MI, Italy), maintained in
microisolator cages and supplied with sterile materials.
Cell culture
The human glioma cell line, U373 MG (astrocytoma grade III) was
obtained from the American Type Culture Collection (Rockville,
MD, USA). The human ovarian carcinoma cell line A2780 was a
kind gift of Dr Franco Zunino, Istituto Nazionale Tumori, Milan,
Italy. Cells were cultured in RPMI-1640 medium containing 10%
heat-inactivated (65°C, 30min) fetal bovine serum with 5mM
HEPES, 2mML-glutamine, 100U ml–1 of penicillin and 100mg
ml–1 of streptomycin at 37°C in an atmosphere of 5% carbon
dioxide. All reagents were purchased from Gibco Laboratories
(Grand Island, NY, USA).
Xenograft model in athymic mice
Tumour xenografts were obtained by subcutaneous (s.c.) injection
of 2 ´107 U373 MG cells or 107 A2780 cells into the right flanks of
female nude mice. Five days after tumour cell inoculation U373
MG or A2780 tumour-bearing mice were randomly divided into
different groups (six animals per group) and treated intravenously
(i.v.) or s.c. as reported in Results. In local treatments all the s.c.
injections of MEN 11467 were sited at about 5mm from the
tumour. MEN 11467 or MEN 11149 were administered at doses
that have been previously shown to produce a complete blockade of
tachykinin NK1-mediated response (bronchoconstriction) elicited
by a systemic administration of Sar9SP, a selective agonist of NK1
tachykinin receptor in guinea pig (Cirillo et al, 1998a, 1998b).
The tumours were measured in two diameters and the tumour
volume (TV) was calculated by the formula: TV = length (mm) ´
width2 (mm)/2 = mm3 (Geran et al, 1972). Optimal tumour volume
inhibition per cent (TVI%) in treated over control mice was evalu-
ated as: 100-(TV treated/TV control ´100) (Geran et al, 1972).
The doubling time in days was measured from a best-fit straight
line of the control tumours in exponential growth (range, 100 4
400mm3).
The non-parametric Mann–Whitney test was used for statistical
comparison of tumour volume in mice treated with NK1 antagonist
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Figure 1Chemical structures of MEN 11149 and MEN 11467versus vehicle treated mice. All animal work was carried out in
accordance with UKCCCR guidelines for the welfare of animals
in experimental neoplasia.
Histological and immunohistochemical studies
At necropsy, tumour masses were preserved in 10% buffered
formol saline. The samples were then dehydrated, embedded in
paraffin wax and sections were cut at 5-mm thickness. Haema-
toxylin and eosin stain was performed in order to evaluate necrotic
areas and inflammatory reactions.
Sections were also stained for SP and glial fibrillary acidic
protein (GFAP) with the indirect immunoperoxidase technique
using the kit specific for rabbit or mouse primary antibodies
(LSAB/HRP, K681 DAKO, Glostrup, Denmark). Specific poly-
clonal rabbit antibodies for SP or GFAP (SIGMA, Chemical Co.,
St Louis, MO, USA) were applied at 1:400 dilution for 2 h at r.t. or
at 1:50 dilution for 15 min at r.t. respectively. At the end of
immunoperoxidase procedures, sections were lightly counter-
stained with haematoxylin for 1 min and automatically mounted
with Tissue Tek Coverslipper, Bayer mod. 4765.
RESULTS
Presence of SP-like immunoreactivity in tumoural area
of U373 MG xenograft in nude mice
Histologically, the U373 MG s.c. xenografted in nude mice retain
some features of a human anaplastic astrocytoma grade III
according to classification of this cell line. A consistent tumour
cellularity, anaplasia, presence of mitotic events and necrosis were
observed. Immunoreactivity of GFAP, a marker of astrocytic
differentiation, was present in the cytoplasm of a proportion of
tumour cells. A gain in tumoural volume was correlated with an
increase in necrotic area. Infiltration of inflammatory cells, mainly
lymphocytes, neutrophils and macrophages was present in the
peripheral area of the tumour and in the perinecrotic zones.
Characteristic patterns of specific GFAP or SP-like immuno-
reactivity in a tumour explant obtained 40 days after U373 MG
implant (vehicle group) are shown in Figure 2. On inspection at
low magnification (253), the presence of SP-like immunoreac-
tivity was observed in the peritumoural skin as well as in various
areas inside the tumour mass, especially in the periphery (Figure
2A). On the other hand, GFAP was localized only in specific areas
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Figure 2 Photomicrograph of cryostat U373 MG xenograft sections immunostained with antibodies to SP or GFAP by indirect immunoperoxidase and
counterstained with haematoxylin. (A, B) SP and GFAP staining, respectively, at low magnification (25´); (C, D) a portion of murine skin (one arrow in panel A)
immunostained with SP and GFAP antibodies respectively (200´); (E, F) a portion of internal tumour section (two arrows in panel A) immunostained with SP
and GFAP antibodies, respectively (200´); (G, H) a portion of peripheral tumour section (three arrows in panel A) immunostained with SP and GFAP antibodies,
respectively (200´)inside the tumour (Figure 2B). At higher magnification (2003),
there was evidence that GFAP staining was restricted only to a
proportion of differentiated astrocytoma cells (Figure 2F). GFAP
immunoreactivity was not observed in the anaplastic undifferenti-
ated U373 MG cells or in the murine cells (Figures 2D, H). The
nervous endings present in the dermal tissue (especially around the
hair bulb, the sebaceous glands (Figure 2C) and in the muscle
fibres (Figure 2G)) of the mouse peritumoural skin showed a
remarkable positivity for SP-like immunoreactivity. In a peripheral
tumoural area, a strong SP-like immunoreactivity was also
observed, although not clearly expressed by tumour cells (Figure
2G). In contrast, specific SP staining was not detected in the more
central tumour zone (Figure 2E). SP-like immunoreactivity was
also found in the peritumoural skin and peripheral tumour areas of
the human ovarian carcinoma A2780 xenograft (data not shown).
Since SP staining is absent in U373 MG cells cultured in vitro
(data not shown), the reported results suggest that the presence of
SP in the xenografted U373 MG tumour mass originates from the
host.
SP-immunoreactivity inside the U373 MG tumour xenograft,
with the characteristics described above, was found in all the
tumour explants (n= 30) analysed independently of the tumoural
volume, the animal treatments (NK1 receptor antagonist and/or SP
exogenous somministration, see below) and the phase of tumoural
growth (data not shown).
SP involvement in glioma growth in vivo483
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Figure 3Response of U373 MG human glioma during the following s.c.
treatment: saline (ll); SP (1mmol kg–1) (l); MEN 11467 (1mmol kg–1) (n);
MEN 11467 (1mmol kg–1) + SP (1mmole kg–1) (administered simultaneously)
(u). Arrows indicate the days of treatment. Each point on the graph indicates
the average volume of six tumours ±s.e.m. Differences from control values
were determined by the non-parametric Mann–Whitney test and are indicated
as follows: *P ≤ 0.05Effect of tachykinin NK1 receptor antagonists on U373
MG xenograft growth in nude mice
To better define the effects of the neuropeptide SP as a tumour
glioma growth factor in vivo, two different schedules of s.c. SP
administration were assayed in nude mice transplanted s.c. to
U373 MG cells. As shown in Figures 3 and 4, both treatments (1
mmole kg–1 twice a week for 2 weeks or 0.4 mmol kg–1 three times
a week for 6 weeks) produced negligible or only slight stimulant
effects on tumour growth, suggesting that the addition of exoge-
nous SP was not necessary for supporting U373 MG in vivo
growth. A role of SP in U373 MG in vivo growth was highlighted
by the anti-tumour activity obtained with SP receptor antagonists.
The pseudopeptide, MEN 11467, which possesses a high affinity
for the human tachykinin NK1 receptor but does not bind the
murine NK1 receptor (Cirillo et al, 1998a), was used to block NK1
receptors expressed in U373 MG cells. As shown in Figure 3, s.c.
treatment with MEN 11467 (1 mmol kg–1 twice weekly for 2
weeks) resulted in a temporary growth arrest of the U373 MG
xenograft that lasted for about 10 days until the last MEN 11467
administration (TVI% = 56). Thereafter, the tumour started to
regrow. MEN 11467 anti-tumour activity was partially reverted by
the simultaneous administration of an equimolar dose of exoge-
nous SP, suggesting the specificity of tachykinin NK1 receptor
activation in glioma growth (Figure 3).
Prolonged s.c. treatment with a higher MEN 11467 dose 
(1.7 mmol kg–1 at five times a week for 6 weeks) completely inhib-
ited the growth of U373 MG tumour for the entire length of the
experiment, even following administration of a low exogenous SP
dose (Figure 4). After 6 weeks, the tumour mass was not increased
compared to the untreated control with TVI% = 96%. At the end of
experiments there was no indication of toxicity following MEN
11467 treatment, either in terms of body weight loss or general
toxicity (data not shown). Under the same experimental condi-
tions, treatment with MEN 11467 (1.7 mmol kg–1 s.c. daily for 3
weeks) did not inhibit the growth of A2780 (Figure 5).
The anti-tumour activity of MEN 11467 was also observed in a
systemic treatment. As shown in Figure 6, i.v. administration with
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Figure 4 Response of U373 MG human glioma during the following s.c.
treatment: saline (l l); SP (0.4 mmol kg–1) three times a week until the end 
of experiment (l); MEN 11467 (1.7 mmol kg–1) five times a week and SP (0.4
mmol kg–1) three times a week until the end of experiment (n). Each point on
the graph indicates the average volume of six tumours ± s.e.m. Differences
from control values were determined by the non-parametric Mann–Whitney
test and are indicated as follows: *P ≤ 0.05
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Figure 5 Response of A2780 human ovarian carcinoma during the
following treatment: saline (l l); MEN 11467 (1.7 mmol kg–1 s.c.) five times a
week until the end of the experiment (n), doxorubicin (7 mg kg–1 i.v.) (s).
Arrows indicate the days of doxorubicin administration. Each point on the
graph indicates the average volume of six tumours ± s.e.m. Differences from
control values were determined by the non-parametric Mann–Whitney test
and are indicated as follows: * P ≤ 0.05
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Figure 6 Response of U373 MG human glioma during the following i.v.
treatment: saline (l l); doxorubicin (7 mg kg–1) (s); MEN 11467 (1 mmol kg–1)
(n). Empty arrows indicate the days of doxorubicin administration while solid
arrows indicate the days of MEN 11467 administration. Each point on the
graph indicates the average volume of six tumours ± s.e.m. Differences from
control values were determined by the non-parametric Mann–Whitney test
and are indicated as follows: *P ≤ 0.05SP involvement in glioma growth in vivo 485
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MEN 11467 (1 mmol kg–1 once daily for 5 consecutive days)
caused a 10-day latency in U373 MG growth in vivo (TVI% = 76).
Similar results in controlling glioma proliferation in vivo were
achieved using the same treatment schedule (1 mmol kg–1 i.v. once
daily for 5 consecutive days), with another specific and selective
human NK1 receptor antagonist, MEN 11149 (Cirillo et al, 1998b)
(TVI% = 54) (Figure 7).
Interestingly, doxorubicin administered at its optimal i.v.
weekly schedule (7 mg kg–1 for 3 consecutive weeks) (Giuliani 
et al, 1981), did not show any anti-tumour activity on U373 MG
xenografts (Figure 6).
DISCUSSION
Astrocytes are responsible for controlling brain homeostasis
through the activation of a variety of responses. Some neurotrans-
mitters, including SP and NKA, are important astrocytic stimuli
representing the link of bidirectional interactions between glial
cells and neurons. The SP-induced release of soluble mediators
and proliferation observed in normal astrocytes (Mantyh et al,
1989; Palma et al, 1997), may be one of the pathways used by
malignant glial cells. We reported a direct role of SP in supporting
the glioma growth and its control by tachykinin NK1 receptor
blockade in an in vivo model. Nude mice transplanted s.c. with
U373 MG cells developed a tumour retaining several features of a
human anaplastic astrocytoma grade III. The murine skin, rich in
nervous fibres containing SP, supplied an endogenous source of
this neuropeptide. Thus the U373 MG xenograft in nude mice was
a suitable in vivo model to verify the role of tachykinin NK1
receptor antagonists in controlling glioma growth.
Blockade of tachykinin NK1 receptors expressed in U373 MG
cells was performed using the tachykinin NK1 receptor antagonist
MEN 11467 which endows high affinity for human NK1 receptor
subtypes but does not bind murine NK1 receptors (Cirillo et al,
1998a). In in vitro assays, MEN 11467 completely inhibited SP-
triggered U373 MG proliferation and cytokine release leaving
unaltered the basal or IL-1b-induced responses as a proof of its
specificity (Palma et al, 1999a). Moreover, MEN 11467 showed a
long-lasting inhibitory activity, probably due to its very slowly
reversible binding to the human tachykinin NK1 receptor (Palma 
et al, 1999b). In fact, a potent inhibition of MEN 11467 in SP-
induced IP1 accumulation, even following its removal from the
external medium, was observed in U373 MG cells (Palma et al,
1999b). Treatment with MEN 11467 was able to control U373 MG
growth in vivo. Prolonged s.c. treatment (1.7 mmol kg–1 five times
a week for 6 weeks) with MEN 11467 inhibited the growth of
U373 MG xenograft for at least 6 weeks. Both s.c. and i.v. admin-
istration of MEN 11467 (1 mmol kg–1) for a short period (1 or 2
weeks) prevented the tumour growth for about 10 days after the
last MEN 11467 administration. The inhibition of tumour prolifer-
ation is not irreversible and a continuous blockade of tachykinin
NK1 receptors is required.
The observed arrest of glioma xenograft growth seems to be
exclusively dependent on the inhibition of SP-stimulated signal
transduction in U373 MG cells. Being MEN 11467 or MEN 11149
highly selective for the human tachykinin NK1 receptor, we
suppose that these drugs did not antagonize the possible SP-
induced responses on murine cells (e.g. endothelial cells) that may
have facilitated U373 MG xenograft growth. In addition, general
toxicity was not observed in mice following s.c. or i.v. treatment
with MEN 11467 or MEN 11149, excluding that the glioma
growth inhibition observed was due to toxic aspecific effects of
these compounds. Moreover, treatment with MEN 11467 did not
alter the growth of A2780 xenograft. This human ovarian carci-
noma cell line, lacking in tachykinin NK1 receptors and unrespon-
sive to SP in terms of cell proliferation and DNA synthesis (our
unpublished observation) was used as a proof to assess the speci-
ficity of tachykinin NK1 receptor activation in glioma growth. In
addition, the role of SP in U373 MG xenograft development was
also supported by the partial reversion of MEN 11467 inhibitory
effects obtained with the simultaneous administration of high
doses of exogenous SP (1 mmol kg–1).
These data suggest an involvement of tachykinins in supporting
glioma progression, although it has to be taken into account the
limitations of the in vivo model used. The microenvironment of a
flank xenograft is very different to that of the central nervous
system and in this model the tachykinin-triggered tumour prolifera-
tion may be relevant compared to other glioma growth factors. In
addition the results were obtained with a single human glioma cell
line, the U373 MG which is highly responsive to SP stimulation
(Luo et al, 1996; Palma et al, 1999a). Although we cannot extrapo-
late the data obtained with U373 MG cells to other cell lines, the
role of tachykinin NK1 receptor activation in human gliomas is
supported by further evidence. In addition to U373 MG cells,
several human glioma cell lines express functional tachykinin NK1
receptors (Ogo et al, 1996; Sharif, 1998; Palma et al, 1999a).
Moreover, the presence of SP receptors in glioma cells is correlated
with a responsiveness to SP in terms of increase in mitogenesis 
and cytokine release (Palma et al, 1999a). The soluble factors
(cytokines, prostaglandins, taurine) induced by SP activation in
glioma cells are themselves tumour growth factors and can in-
fluence the tumour cell–host interactions including depression 
of the immune response, angiogenesis and microenvironment
modifications (Jennings et al, 1991; Munoz-Fernandes and Fresno,
1993; Gillespie, 1996). Heterogeneity of human gliomas regarding
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Figure 7 Response of U373 MG human glioma during the following i.v.
treatment: saline (l l); MEN 11149 (1 mmol kg–1) (l). Solid arrows indicate the
days of MEN 11149 administration. Each point on the graph indicates the
average volume of six tumours ± s.e.m. Differences from control values were
determined by the non-parametric Mann–Whitney test and are indicated as
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their SP responsiveness and consequently their different suscepti-
bility to tachykinin NK1 receptor antagonist treatment, may be
dependent on the origin of the transformed astrocytes. Differences
in expression of tachykinin NK1 receptors and in SP responsiveness
were observed in human embryonic spinal cord or myelecephalon/
mesencephalon astrocytes (Palma et al, 1997). In addition, it would
be interesting to discover if differentiated and more anaplastic
glioma cells, present also in U373 MG xenograft (GFAP + and
GFAP – cells, respectively) express the same amount of tachykinin
NK1 receptors and if their activation induces comparable responses.
The possible involvement of the neurotransmitter SP in gliomas
is also supported by some clinical findings. In human brain biop-
sies of glioma patients, the presence of the neuropeptide SP as well
as the presence of tachykinin NK1 receptors have been observed
(Allen et al, 1985; Henning et al, 1995). Nine out of 12 astro-
cytomas and 10 out of 10 glioblastomas were positive for SP
receptors, with an increasing percentage of tachykinin NK1
receptor expression in tumours possessing the most malignant
phenotype (Henning et al, 1995). In addition, the expression of
tachykinin NK1 receptors in peritumoural and tumoural blood
vessels (Henning et al, 1995) suggests a role of SP in facilitating
tumour blood supply by virtue of its tachykinin NK1 receptor-
mediated angiogenic and vasodilator properties (Ziche et al, 1990).
Although we were not able to detect a direct SP production by
U373 MG in vivo, astrocytes themselves may be a source of 
this neuropeptide. Cultured astrocytes express mRNA for pre-
protachykinin, the precursor of SP (Too et al, 1994), and SP
immunoreactivity or mRNA have been localized in reactive astro-
cytes in white matter lesions of multiple sclerosis brains (Kostyk et
al, 1989) and in a mouse model of axonal degeneration (Yamazaki
et al, 1993). In addition, a glial-cell-line-derived neurotrophic
factor enhanced biosynthesis of SP in striatal neurons (Humpel et
al, 1996), suggesting a modulation of SP release by astrocytes.
The tachykinin NK1 receptor antagonist efficacy in a glioma in
vivo model is an important finding as, at present, no curative
therapy is available for malignant gliomas. The median survival of
glioma patients treated with standard cytoreductive surgery and
post-operative radiotherapy or chemotherapy is in the range of 1
year. In nude mice transplanted s.c. to U373 MG, no significant
reduction in final tumour volume was obtained with doxorubicin,
one of the most clinically useful cytotoxic drugs. The lack of cyto-
toxic effects by doxorubicin in our glioma in vivo model may be
due to the low growth kinetics of U373 MG tumour in nude mice
(doubling time = 7 4 8 days) and, especially, to the intrinsic resis-
tance of U373 MG cells. These astrocytoma cells overexpress the
multidrug resistance (mdr1) gene and its product, P-glycoprotein,
as well as the multidrug resistance-associated protein (Walther et
al, 1995; Masanao, 1998).
In conclusion, we have gathered evidence that SP, through
tachykinin NK1 receptor activation, participates in U373 MG
development and growth in vivo. Besides the limitations of the
model proposed regarding the glioma growth in a micro-
environment very different from the central nervous system and
the use of just one human cell line, this study introduces the novel
idea of a therapeutic approach with tachykinin NK1 receptor antag-
onists to treat malignant gliomas. The incomplete knowledge of
the role of tachykinins in the human central nervous system does
not allow, at present, to foresee the side effects of a prolonged
treatment with tachykinin NK1 receptor antagonists.
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